表紙
市場調査レポート

プレフィルシリンジ:世界市場の見通し

Pre-Filled Syringes Market Forecast 2016-2026: Prospects for Leading Companies in Plastic Pre-Filled Syringes, Pen Injector & Autoinjectors, and Glass Pre-Filled Syringes

発行 Visiongain Ltd 商品コード 206673
出版日 ページ情報 英文 206 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.81円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
プレフィルシリンジ:世界市場の見通し Pre-Filled Syringes Market Forecast 2016-2026: Prospects for Leading Companies in Plastic Pre-Filled Syringes, Pen Injector & Autoinjectors, and Glass Pre-Filled Syringes
出版日: 2016年03月31日 ページ情報: 英文 206 Pages
概要

世界のプレフィルシリンジ市場は、2020年に69億4,000万米ドルの規模に達する見込みで、2026年まで安定した成長を続けると予測しています。新たな注射剤の増加および開発の進歩などが市場成長の要因として挙げられます。

当レポートでは、世界のプレフィルシリンジ市場について調査分析し、市場の収益予測(今後11年間分)や、成長率、市場シェア、技術動向、製品別・地域別・治療分野別の詳細動向・予測、今後の市場の機会と課題などについてまとめてお届けいたします。

第1章 レポート概要

第2章 プレフィルシリンジ市場のイントロダクション

  • プレフィルシリンジとは?
  • プレフィルシリンジの略史
  • プレフィルシリンジの設計と製造
  • ペン型注射器・オートインジェクターの概略
  • ガラス製とプラスチック製
  • プレフィルシリンジの今後の方向性
  • 市場区分
  • 調査範囲
  • 本レポートにおける為替レート

第3章 世界市場の見通しと予測

  • 世界のドラッグデリバリー市場におけるシェア
  • 世界のプレフィルシリンジ市場
  • 価格ベースの売上予測
  • セグメント別市場シェア予測
  • 成長促進因子と抑制因子
  • ガラス製プレフィルシリンジ市場の予測
  • プラスチック製プレフィルシリンジ市場の予測
  • ペン型注射器・オートインジェクター市場の予測

第4章 主要国市場の予測

  • 世界のプレフィルシリンジ市場:国別内訳
  • 主要国のプレフィルシリンジ市場
  • 世界のプレフィルシリンジ市場:地域別内訳
  • 地域別市場予測
  • 米国のプレフィルシリンジ市場の予測
  • 日本のプレフィルシリンジ市場の予測
  • EU5ヵ国のプレフィルシリンジ市場の予測
  • 新興国のプレフィルシリンジ市場(中国・インド・ロシア・ブラジル)

第5章 プレフィルシリンジの主な治療分野の見通し

  • プレフィルシリンジおよび他の注射装置の主な治療分野
  • 糖尿病向けプレフィルシリンジおよびペン型注射器:市場予測
  • リウマチ性関節炎
  • 多発性硬化症向け自己注射:市場展望
  • 成長ホルモン:市場展望
  • プレフィル・ヘパリン・シリンジ:市場予測
  • ワクチン:市場展望
  • PCSK9 インヒビター:市場予測

第6章 プレフィルを用いる代表的な治療方法

  • ペン型注射器を用いる主なインスリン療法
    • Lantus:世界的ベストセラーのインスリン類似体
    • NovoLog:代表的な即効性インスリン
    • Humalog
  • リウマチ性関節炎向けの主な生物製剤:市場展望
    • Humira:世界最大の売上高となった薬剤
    • Enbrel:Humiraの最大のライバル
  • 多発性硬化症:代表的な注射療法
    • Copaxone:注射式の非インターフェロン療法
    • Avonex
    • Rebif
  • 成長ホルモン市場:2種類の医薬品による独占状態
    • Norditropin
    • Genotropin
  • PCSK9 製品:市場の見通し
    • Praluent (alirocumab, Sanofi/Regeneron)
    • Repatha (evolocumab, Amgen)

第7章 プレフィルシリンジおよび関連製品の主要メーカー

  • 代表的なプレフィルシリンジメーカー
    • BD:最大の市場リーダー
    • Gerresheimer
    • Schott
    • その他の注目企業
  • 代表的なペン型注射器・オートインジェクターメーカー
    • SHL Group
    • Ypsomed
    • Haselmeier
    • Owen Mumford
    • Bespak:新規参入者
    • その他
  • 代表的なプレフィルシリンジ用部品メーカー
    • Datwyler
    • West Pharmaceutical Services

第8章 プレフィルシリンジ市場の定量分析

  • SWOT分析(強み、弱み、機会、脅威)
  • STEP分析(社会的・技術的・経済的・政治的要因)
  • 規制面・安全面での見通し
  • 生物製剤とプレフィルシリンジ市場の見通し
  • プレフィルシリンジ産業の発展・成長における患者の役割
  • プレフィルシリンジの技術開発の見通し
  • プレフィルシリンジ産業におけるアウトソーシング

第9章 専門家の見解

  • 主要メーカー Nemeraへの取材

第10章 分析の結論

第11章 用語集

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0103

What can be expected from the pre-filled syringes market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 206-page report provides 123 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall regional market and national level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and STEP analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2026? Our study forecasts revenues in the following national submarkets:

  • National and Regional Markets
  • Leading Therapeutic Sectors
  • Leading Pre-Filled Device Therapies
  • Pre-Filled Syringe and Related Technology Manufacturers

Leading companies and potential for market growth

Overall revenue for the Pre-filled syringe market will reach $6,940m in 2020, our work forecasts. We predict strong revenue growth through to 2026. A number of new injectable drugs and advances in technology are seen as factors driving growth over the forecast period.

Our work analyses the key companies in the market. See visiongain's analysis of 14 leading companies, including these:

  • Becton, Dickinson and Company
  • Gerresheimer
  • Schott
  • Baxter
  • Nipro
  • Weigao
  • Unilife
  • Roselabs
  • SHL Group
  • Ypsomed
  • Haselmeier
  • Owen Mumford
  • Bespak
  • Datwyler

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Company news relevant to the market
  • Historical revenues

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the Pre-Filled Syringe industry?

Our new report discusses issues and events affecting the pre-filled syringe market. You will find discussions, including qualitative analyses on a range of topics. You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Pre-Filled Syringes Market 2016-2026 report helps you

In summary, our 206-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Pre-Filled Syringes market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for the leading national markets - US, Japan, EU5, BRIC
  • Revenue forecasts to 2026 for submarkets - discover prospects for leading therapeutic areas, as well as products within these areas. Identify the key trends driving and restraining growth in the market, including government policy and economic conditions relevant to the market.
  • Assessment of 14 leading companies - historical revenue, news and upcoming product releases
  • Discussion of what stimulates and restrains the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the pre-filled syringes market and leading companies. You will find data, trends and predictions. Please order our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Pre-Filled Syringes Market Overview
  • 1.2. Global Pre-Filled Syringes Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Pre-Filled Syringes

  • 2.1. What are Pre-Filled Syringes?
  • 2.2. A Brief History of Pre-Filled Syringes
  • 2.3. Design and Manufacture of Pre-Filled Syringes
    • 2.3.1. Glass and Plastic Syringes
    • 2.3.2. Safety and the Pre-Filled Syringe Market
    • 2.3.3. Concerns over Needlestick Injuries
  • 2.4. An Introduction to Pen Injectors and Autoinjectors
    • 2.4.1. Pen Injectors and Autoinjectors Offer Advantages in Self-Administration
    • 2.4.2. What Determines Injection Device Choice?
  • 2.5. Glass versus Plastic
    • 2.5.1. Glass
    • 2.5.2. Plastic
  • 2.6. Future Directions for Pre-Filled Syringes
  • 2.7. Pre-Filled Syringes: Market Segmentation
  • 2.8. Scope of this Report
    • 2.8.1. Products Excluded from this Report
  • 2.9. Currency Exchange Rates in This Report

3. Pre-Filled Syringes: World Market 2016-2026

  • 3.1. Pre-Filled Syringes as a Share of the Global Drug Delivery Market
  • 3.2. The World Pre-Filled Syringes Market in 2015
    • 3.2.1. World Pre-Filled Syringes Market: Market Shares by Segment 2015
    • 3.2.2. Leading Companies in the Pre-Filled Syringes Market
  • 3.3. World Pre-Filled Syringes Market: Sales Forecast by Value, 2016-2026
  • 3.4. How Will Segmental Market Shares Change to 2026?
  • 3.5. World Pre-Filled Syringes Market: Drivers and Restraints 2016-2026
    • 3.5.1. Biologics and Biosimilars to Drive Market Growth
    • 3.5.2. Human Factors and Regulatory Requirements
    • 3.5.3. Advances in Pre-Filled Syringe Manufacturing
    • 3.5.4. Market Genericisation and Pre-Filled Syringes
    • 3.5.5. The Injectable Drug Pipeline is Substantial
    • 3.5.6. Competing Drug Delivery Technologies
  • 3.6. Glass Pre-Filled Syringes Lead the Pre-Filled Syringes Market
    • 3.6.1. Glass Pre-Filled Syringes Market: Sales Forecast by Value, 2016-2026
    • 3.6.2. Glass Pre-Filled Syringes: Drivers and Restraints 2016-2026
  • 3.7. Plastic Pre-Filled Syringes: Rapid Growth Forecasted
    • 3.7.1. Plastic Pre-Filled Syringes Market: Sales Forecast by Revenue, 2016-2026
    • 3.7.2. Plastic Pre-Filled Syringes: Drivers and Restraints 2016-2026
  • 3.8. Pen Injectors and Autoinjectors: A Growing Segment
    • 3.8.1. Pen Injectors and Autoinjectors Market: Sales Forecast by Value, 2016-2026
    • 3.8.2. Pen Injectors and Autoinjectors: Drivers and Restraints 2016-2026
    • 3.8.3. Insulin and Other Biologics to Lead Market Growth

4. Leading National and Regional Markets 2016-2026

  • 4.1. National Breakdown of the World Pre-Filled Syringes Market
  • 4.2. World Pre-Filled Syringes Market: National Markets Forecast 2016-2026
    • 4.2.1. How Will National Market Shares Change to 2026?
  • 4.3. Regional Breakdown of the World Pre-Filled Syringes Market
  • 4.4. World Pre-Filled Syringes Market: Regional Markets Forecast 2016-2026
    • 4.4.1. How Will Regional Market Shares Change to 2026?
  • 4.5. US Pre-Filled Syringes Market Forecast 2016-2026
    • 4.5.1. US Pre-Filled Syringes Market: Trends and Developments
      • 4.5.1.1. New Drug and Device Launches to Drive Growth to 2026
      • 4.5.1.2. The Budget Control Act 2011 and the Medical Excise Tax
  • 4.6. Japanese Pre-Filled Syringes Market Forecast 2016-2026
  • 4.7. EU5 Pre-Filled Syringes Market Forecast 2016-2026
  • 4.8. Emerging Markets: Pre-Filled Syringes Market Forecast 2016-2026
    • 4.8.1. Pre-Filled Syringe Manufacturers Are Investing in Emerging Markets
    • 4.8.2. Chinese Pre-Filled Syringes Market Forecast 2016-2026
    • 4.8.3. Indian Pre-Filled Syringes Market Forecast 2016-2026
    • 4.8.4. Russian Pre-Filled Syringes Market Forecast 2016-2026
    • 4.8.5. Brazilian Pre-Filled Syringes Market Forecast 2016-2026

5. Leading Therapeutic Sectors for Pre-Filled Syringes 2016-2026

  • 5.1. Leading Therapeutic Sectors for Pre-Filled Syringes and Other Injection Devices in 2015
    • 5.1.1. Vaccines and Heparins Are Major Market Sectors
    • 5.1.2. Rising Demand in Chronic Conditions: Autoimmune Diseases and Diabetes
    • 5.1.3. Growth for Key Market Sectors 2016-2026
  • 5.2. Pre-Filled Syringes and Pen Injectors for Diabetes 2016-2026
    • 5.2.1. Insulin Market Forecast 2016-2026
    • 5.2.2. High Rates of Pen Injector Use in the EU and Japan
    • 5.2.3. Insulin Pumps: A Technology to Challenge Pen Injectors to 2026?
    • 5.2.4. MannKind's Afrezza: Inhalable Insulin Approved in US
    • 5.2.5. Injection Devices for Biosimilar Insulin Products
  • 5.3. Rheumatoid Arthritis: Leading Biologics Dominate the Market
    • 5.3.1. Rheumatoid Arthritis Market Forecast 2016-2026
    • 5.3.2. All Major Injectable Therapies Are Marketed in Proprietary Devices
    • 5.3.3. Novel Injection Systems for RA: Meeting the Needs of Patients
    • 5.3.4. The Receding Threat from Oral Therapies to 2026
  • 5.4. Growth Hormones: Outlook to 2026
    • 5.4.1. Growth Hormones Market Forecast 2016-2026
    • 5.4.2. Biosimilar Growth Hormones and Pen Injectors
    • 5.4.3. Uptake of Needle-Free Injectors for Growth Hormones
  • 5.5. The Vaccine Market Outlook 2016-2026
    • 5.5.1. Vaccine Market Forecast 2016-2026
    • 5.5.2. Single-Use Devices for Vaccine Delivery
      • 5.5.2.1. BD Uniject: A Private-Public Collaboration
    • 5.5.3. Needle-Free Injectors for Vaccines
    • 5.5.4. Other Trends in Vaccine Delivery
  • 5.6. PCSK9 Inhibitors: The Next Advance in Cholesterol-Lowering Drugs
    • 5.6.1. PCSK9 Inhibitors Market Forecast 2016-2026
    • 5.6.2. PCSK9 Inhibitors and Pre-Filled Syringes/Injectors

6. Leading Pre-Filled Device Therapies 2016-2026

  • 6.1. Leading Insulin Therapies Using Pen Injectors 2016-2026
    • 6.1.1. Lantus: The World's Best-Selling Insulin Analogue
      • 6.1.1.1. SoloSTAR, ClikSTAR and AllSTAR: Three Pen Injectors for Lantus
      • 6.1.1.2. Lantus: Sales Forecast 2016-2026
    • 6.1.2. NovoLog: The Leading Fast-Acting Insulin
      • 6.1.2.1. NovoLog FlexPen: To Be Retired
      • 6.1.2.2. Novo's New FlexTouch Pen Launched
      • 6.1.2.3. NovoLog: Sales Forecast 2016-2026
    • 6.1.3. Humalog
      • 6.1.3.1. Humalog: HumaPen and KwikPen
      • 6.1.3.2. Humalog: Sales Forecast 2016-2026
  • 6.2. Top Biologics for Rheumatoid Arthritis: Device Outlook to 2026
    • 6.2.1. Humira: The Biggest-Selling Drug in 2015
      • 6.2.1.1. The Humira Pen Is an Innovative Delivery Device
      • 6.2.1.2. Humira: Sales Forecast 2016-2026
    • 6.2.2. Enbrel: The Leading Competitor to Humira
      • 6.2.2.1. Pre-Filled Injection Devices Available for Enbrel in 2015
      • 6.2.2.2. Enbrel: Sales Forecast 2016-2026
  • 6.3. Growth Hormones: Two Products Dominated the Market in 2015
    • 6.3.1. Norditropin: the Leading Growth Hormone
      • 6.3.1.1. Norditropin: Sales Forecast 2016-2026
    • 6.3.2. Genotropin: Sales Forecast 2016-2026
  • 6.4. Outlook for Leading PCSK9 Products 2016-2026
    • 6.4.1. Praluent (alirocumab, Sanofi/Regeneron)
      • 6.4.1.1. Praluent: Sales Forecast 2016-2026
      • 6.4.1.2. Amgen Suit Against Sanofi/Regeneron's Praluent
    • 6.4.2. Repatha (evolocumab, Amgen)
      • 6.4.2.1. Repatha: Sales Forecast 2016-2026

7. Leading Pre-Filled Syringe and Related Technology Manufacturers, 2016

  • 7.1. Leading Pre-Filled Syringe Manufacturers in 2015
    • 7.1.1. Becton, Dickinson & Company: The Market Leader
      • 7.1.1.1. Becton, Dickinson & Company: Pre-Filled Syringes Product Portfolio
      • 7.1.1.2. BD Historical Revenue and Market Prospects
      • 7.1.1.3. Recent Acquisitions by BD
      • 7.1.1.4. BD Acquisition of CareFusion
      • 7.1.1.5. BD AutoShield Duo Pen Needle Launched in 2014
    • 7.1.2. Gerresheimer
      • 7.1.2.1. Gerresheimer: Pre-Filled Syringes Product Portfolio
      • 7.1.2.2. Gerresheimer Historical Revenue 2014-2015 and Market Outlook
      • 7.1.2.3. Gerresheimer: Products in Development
      • 7.1.2.4. Patent Application for Gerresheimer's Gx G-Fix Adapter
      • 7.1.2.5. Gerresheimer Commissioned to Manufacture Simponi Autoinjectors
      • 7.1.2.6. Gerresheimer Opens First Development Center in China
    • 7.1.3. Schott
      • 7.1.3.1. Schott: Pre-Filled Syringes Product Portfolio
      • 7.1.3.2. Schott Historical Revenue and Market Prospects
      • 7.1.3.3. Schott: Expansion in India
  • 7.2. Other Notable Pre-Filled Syringe Manufacturers
    • 7.2.1. Baxter: Providing Contract Manufacturing with Pre-Filled Syringes
    • 7.2.2. Nipro: Leading Japanese Contract Manufacturer
      • 7.2.2.1. Nipro's 2012 Acquisition of MGlas
    • 7.2.3. Stevanato Group/Ompi: Insulin Vials Market Leader
    • 7.2.4. Weigao: Pre-Filled Syringes for China and Beyond
    • 7.2.5. Unilife: Pre-Filled Safety Syringes
    • 7.2.6. Roselabs: Entered the Market in 2012
    • 7.2.7. Vetter Pharma: Offering Lyo-Ject Dual-Chamber Syringes
    • 7.2.8. Other Companies
  • 7.3. Leading Pen Injector and Autoinjector Manufacturers in 2015
    • 7.3.1. SHL Group
      • 7.3.1.1. SHL Group: Pen Injectors and Autoinjectors Product Portfolio
      • 7.3.1.2. SHL Group Market Prospects
    • 7.3.2. Ypsomed
      • 7.3.2.1. Ypsomed: Pen Injectors and Autoinjectors Product Portfolio
      • 7.3.2.2. Ypsomed Historical Revenue and Market Prospects
      • 7.3.2.3. Ypsomed: Recent Developments
    • 7.3.3. Haselmeier
      • 7.3.3.1. Haselmeier: Pen Injectors and Autoinjectors Product Portfolio
      • 7.3.3.2. Haselmeier: Market Prospects
    • 7.3.4. Owen Mumford
      • 7.3.4.1. Owen Mumford: Pen Injectors and Autoinjectors Product Portfolio
    • 7.3.5. Bespak: Entering the Auto-Injectors Market
    • 7.3.6. Other Leading and Emerging Autoinjector Manufacturers
  • 7.4. Leading Pre-Filled Syringe Component Manufacturers in 2016
    • 7.4.1. Datwyler
      • 7.4.1.1. Datwyler Historical Revenue and Market Prospects

8. Qualitative Analysis of the Pre-Filled Syringes Market 2016-2026

  • 8.1. SWOT Analysis of the Pre-Filled Syringes Market
  • 8.2. Strengths
    • 8.2.1. Pre-Filled Syringes and Pen/Autoinjectors are Used In Chronic Conditions
    • 8.2.2. Device Manufacturers Offer a Range Of Products
    • 8.2.3. Customisation and Product Differentiation
    • 8.2.4. Effective Lifecycle Management
  • 8.3. Weaknesses
    • 8.3.1. Patients with Needle Phobia
    • 8.3.2. Chronic Diseases May Make Pre-Filled Syringes Difficult to Use
    • 8.3.3. Risk of Extractables and Leachables
    • 8.3.4. Higher Cost and Greater Cold Chain and Storage Requirements
  • 8.4. Opportunities
    • 8.4.1. Biosimilars Represent a Growing Market
    • 8.4.2. Viscous and Large-Volume Drugs Require Novel Devices
    • 8.4.3. Technological Developments Expanding Product Portfolios
    • 8.4.4. Many Injectable Drugs in the Pipeline
    • 8.4.5. Growth in Emerging Markets
  • 8.5. Threats
    • 8.5.1. Alternative Technologies: Needle-Free and Bolus Injectors
    • 8.5.2. New Oral Therapies for Many Chronic Conditions
    • 8.5.3. Increasing Regulatory Barriers
    • 8.5.4. Cost Pressures on Healthcare Payers
  • 8.6. STEP Analysis of the Pre-Filled Syringes Market
    • 8.6.1. Social Factors: Rising Disease Incidence and Demand for At-Home Care
    • 8.6.2. Technological Developments: Improved Safety and Administration
    • 8.6.3. Economic Pressures: Pre-Filled Syringes Are Cost Efficient
      • 8.6.3.1. High Barriers to Market Entry Exist
    • 8.6.4. Political Issues: Regulatory Developments for Pre-Filled Syringes
  • 8.7. Regulatory and Safety Outlook for Pre-Filled Syringes, 2016-2026
    • 8.7.1. Needlestick Safety and Prevention
    • 8.7.2. International Regulations for Needlestick Prevention
      • 8.7.2.1. The US: The First Country to Introduce Needlestick Legislation
      • 8.7.2.2. The EU: New Rules from 2013 Onwards
      • 8.7.2.3. Needlestick Safety in Japan
      • 8.7.2.4. Legislation for Needlestick Safety in Emerging Markets
    • 8.7.3. Manufacturers Will Continue to Develop New Devices for Needlestick Prevention
      • 8.7.3.1. Ancillary versus Integrated Safety Devices
    • 8.7.4. Extractables and Leachables
      • 8.7.4.1. Companies Will Reduce Sources of Extractables and Leachables
      • 8.7.4.2. Products that Minimise Extractables and Leachables
      • 8.7.4.3. Protein Aggregation: The Challenge of Biological Drugs
      • 8.7.4.4. Regulatory Requirements for Extractables and Leachables
  • 8.8. Biologics and the Pre-Filled Syringes Market, 2016-2026
    • 8.8.1. Manufacturing Pre-Filled Syringes for Biologics: Glass versus Plastic
    • 8.8.2. Biologics Provide New Challenges for Device Manufacturers
      • 8.8.2.1. Lyophilised Drugs and Dual-Chamber Devices
    • 8.8.3. Delivery Opportunities for High Viscosity Drugs
    • 8.8.4. Are Biosimilars an Opportunity for Pre-Filled Syringe Manufacturers?
  • 8.9. The Role of Patients in Pre-Filled Syringe Industry Development and Growth
    • 8.9.1. Chronic Disease Incidence 2016-2026
    • 8.9.2. The Rise in At-Home Care
    • 8.9.3. Improving Patient Adherence
    • 8.9.4. Injection Devices Must be Developed for Patient Convenience: Human Factors Engineering
  • 8.10. Technological Developments in Pre-Filled Syringes to 2026
    • 8.10.1. Product Differentiation Will be Vital in Crowded Treatment Markets
    • 8.10.2. Product Customisation: Adapting Injection Devices
    • 8.10.3. Trends in Manufacturing Materials for Pre-Filled Syringes
    • 8.10.4. Competing Technologies Will Challenge Pre-Filled Syringes
      • 8.10.4.1. Will Needle-Free Devices Become a Significant Competing Technology?
      • 8.10.4.2. Patients Prefer Oral Drug Delivery
  • 8.11. Outsourcing in the Pre-Filled Syringe Industry
    • 8.11.1. Contract Medical Device Manufacturing
    • 8.11.2. Contract Filling of Pre-Filled Syringes

9. Research Interviews

  • 9.1. Interview with Nemera
    • 9.1.1. Drivers and Restraints in the Pre-Filled Syringes Market
    • 9.1.2. State of the Emerging Markets
    • 9.1.3. Greatest Unmet Need in the Market
    • 9.1.4. Therapeutic Areas Set to Benefit
    • 9.1.5. Therapeutic Areas Set to Benefit
    • 9.1.6. Nemera's Safe'n'Sound Products
    • 9.1.7. Other Nemera Products

10. Conclusions

  • 10.1. Pre-Filled Syringes and Pen/Autoinjectors: Strong Growth Expected
  • 10.2. The World Pre-Filled Syringes Market in 2015
    • 10.2.1. Current Leading Pre-Filled Syringes Segments
    • 10.2.2. Leading Pre-Filled Syringes Companies
    • 10.2.3. Leading National and Regional Markets
  • 10.3. World Pre-Filled Syringes Market Forecast 2016-2026
  • 10.4. The Future of the Pre-Filled Syringes Market?
    • 10.4.1. Glass Syringes Will Continue to Dominate
    • 10.4.2. Innovation for Growth

11. Glossary

Appendix

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 2.1: Currency Exchange Rates, 2015
  • Table 3.1: World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Segment, 2015-2026
  • Table 3.2: Market Shares (%) of Leading Pre-Filled Syringes Market Segments, by Revenue, 2015, 2020 and 2026
  • Table 3.3: Glass Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.4: Selected Proprietary Polymers for Plastic Pre-Filled Syringes, 2015
  • Table 3.5: Plastic Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.6: Pen Injectors and Autoinjectors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.1: World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by National Market, 2015
  • Table 4.2: World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
  • Table 4.2: World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026 (continued)
  • Table 4.3: Market Shares (%) of Leading National Pre-Filled Syringes Markets, 2015, 2020 and 2026
  • Table 4.4: World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by Regional Market, 2015
  • Table 4.5: World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Regional Market, 2015-2026
  • Table 4.6: Market Shares (%) of Leading Regional Pre-Filled Syringes Markets, 2015, 2020 and 2026
  • Table 4.7: US Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.8: Japanese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.9 : U5 Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
  • Table 4.10: Chinese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.11: Indian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.12: Russian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.13: Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.1: Pen Manufacturing Agreements for Leading Insulin Brand Manufacturers, 2015
  • Table 5.2: Selected Biosimilar Insulin Pen Injectors, 2016
  • Table 5.3: Insulin Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.4: Rheumatoid Arthritis Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.5: Growth Hormone Therapies in Pen Injectors, 2016
  • Table 5.6: Growth Hormones Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.7: Selected Biosimilar Growth Hormones in Emerging Markets, 2016
  • Table 5.8: Vaccines Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.9: PCSK9 Inhibitors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.1: Leading Pre-Filled Insulin Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.2: Sanofi: Lantus Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.3: Novo Nordisk: NovoLog Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.4: Eli Lilly: Humalog Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.5: Leading Pre-Filled Rheumatoid Arthritis Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.6: AbbVie/Eisai: Humira Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.7: Amgen/Pfizer: Enbrel Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.8: Leading Pre-Filled Growth Hormone Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.9: Novo Nordisk: Norditropin Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.10: Pfizer: Genotropin Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.11: Sanofi: Praluent Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.12: Amgen: Repatha Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.1: BD: Overview, 2016
  • Table 7.2: BD: Pre-Filled Injection Systems, 2016
  • Table 7.3: BD: Pharmaceutical Systems Revenue ($m), AGR (%), CAGR (%), 2010-2015
  • Table 7.4: Gerresheimer: Overview, 2016
  • Table 7.5: Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m) for 2014 and 2015, plus AGR (%)
  • Table 7.6: Schott: Overview, 2016
  • Table 7.7: Schott: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 7.8: Unilife: Pre-Filled Syringe Product Portfolio, 2016
  • Table 7.9: Unilife: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 7.10: SHL Group: Overview, 2016
  • Table 7.11: SHL Group: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.12: Ypsomed: Overview, 2016
  • Table 7.13: Ypsomed: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.14: Ypsomed: Delivery Devices Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 7.15: Haselmeier: Overview, 2016
  • Table 7.16: Haselmeier: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.17: Owen Mumford: Overview, 2016
  • Table 7.18: Owen Mumford: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.19: Datwyler: Overview, 2016
  • Table 7.20: Datwyler: Pharma Packaging Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 8.1: Benefits and Weaknesses to Pre-Filled Syringes as an Injectable Delivery Device, 2016
  • Table 8.2: Pre-Filled Syringes Market: STEP Analysis, 2016-2026
  • Table 8.3: Selected Safety Products for Pre-Filled Syringes, 2016
  • Table 8.4: Selected Pre-Filled Injection Devices for Lyophilised Drugs, 2016
  • Table 8.5: Pre-Filled Syringe Manufacturers: Alternative Injectable Technologies, 2016
  • Table 8.6: Selected Insulin Pumps Available, 2016
  • Table 8.7: Oral Drug Competitors for Leading Pre-Filled Syringe Therapeutic Sectors, 2016-2026
  • Table 8.8: Selected Leading CMOs: Pre-Filled Syringe Filling Capabilities, 2016

List of Figures

  • Figure 1.1: Global Pre-Filled Syringes Market Segmentation Overview, 2016
  • Figure 2.1: Diagram of Syringe Parts, 2015
  • Figure 2.2: Timeline of Pre-Filled Syringe Development, 1950-2015
  • Figure 2.3: Major Trends for Pre-Filled Syringe Market Growth, 2016
  • Figure 3.1: World Pre-Filled Syringes Market: Market Shares (%) by Segment, 2015
  • Figure 3.2: World Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 3.3: World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2015
  • Figure 3.4: World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2020
  • Figure 3.5: World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2026
  • Figure 3.6: World Pre-Filled Syringes Market: Drivers and Restraints, 2016-2026
  • Figure 3.7: Glass Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 3.8: Glass Pre-Filled Syringes Market: Drivers and Restraints, 2016-2026
  • Figure 3.9: Plastic Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 3.10: Plastic Pre-Filled Syringes Market: Drivers and Restraints, 2016-2026
  • Figure 3.11: Pen Injectors and Autoinjectors Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 3.12: Pen Injectors and Autoinjectors Market: Drivers and Restraints, 2016-2026
  • Figure 4.1: World Pre-Filled Syringes Market: Revenues ($m) by National Market, 2015
  • Figure 4.2: World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2015
  • Figure 4.3: World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2020
  • Figure 4.4: World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2026
  • Figure 4.5: World Pre-Filled Syringes Market: Revenues ($m) by Regional Market, 2015
  • Figure 4.6: World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2015
  • Figure 4.7: World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2020
  • Figure 4.8: World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2026
  • Figure 4.9: US Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 4.10: Japanese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 4.11: EU5 Pre-Filled Syringes Market Forecast: Revenues ($m) by National Market, 2015-2026
  • Figure 4.12: Chinese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 4.13: Indian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 4.14: Russian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 4.15: Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 5.1: Insulin Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 5.2: Rheumatoid Arthritis Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 5.3: Growth Hormones Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 5.4: Vaccines Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 5.5: PCSK9 Inhibitors Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 6.1: Sanofi: Lantus Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.2: Novo Nordisk: NovoLog Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.3: Eli Lilly: Humalog Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.4: AbbVie/Eisai: Humira Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.5: Amgen/Pfizer: Enbrel Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.6: Novo Nordisk: Norditropin Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.7: Pfizer: Genotropin Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.8: Sanofi/Regeneron: Praluent Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.9: Amgen: Repatha Revenue ($m) and AGR (%), 2015-2026
  • Figure 7.1: BD: Pharmaceutical Systems Revenue ($m), AGR (%), 2010-2015
  • Figure 7.2: Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m), 2014 and 2015
  • Figure 7.3: Schott: Net Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.4: Unilife: Net Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.5: Ypsomed: Delivery Devices Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.6: Datwyler: Pharma Packaging Revenue ($m) and AGR (%), 2010-2015
  • Figure 8.1: Pre-Filled Syringes Market: Strengths and Weaknesses, 2016-2026
  • Figure 8.2: Pre-Filled Syringes Market: Opportunities and Threats, 2016-2026
  • Figure 10.1: World Pre-Filled Syringes Market Forecast: Revenues ($m) by Segment, 2015-2026

Companies Listed

  • Abbvie
  • Ache
  • Amega Biotech
  • Amgen
  • Antares Pharma
  • Aptar Stelmi
  • AstraZeneca
  • Baxter International
  • Becton, Dickinson and Company
  • Bespak
  • Biocon
  • Bioject Medical Technologies
  • Biomarin
  • Biosidus
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • CareFusion Corporation
  • Celgene
  • Centocor
  • Daikyo Seiko
  • Datwyler
  • Dong-A
  • Dr. Reddy's
  • Eisai Pharmaceutical
  • Eli Lilly
  • Ferring
  • Gan & Lee
  • GeneScience Pharmaceuticals
  • Gerresheimer
  • GlaxoSmithKline
  • Haselmeier
  • Helvoet Pharmaceutical
  • Hospira
  • Incepta Pharmaceuticals
  • Janssen Biotech
  • Johnson and Johnson
  • LG Life Sciences/Biopartners
  • Mannkind
  • Merck & Co
  • Merck Serono
  • Mitsubishi Tanabe
  • Nektar Therapeutics
  • Nipro
  • Novartis
  • Novo Nordisk
  • OPKO Health
  • Oval Medical
  • Owen Mumford
  • PA Consulting Group
  • Palatin Technologies
  • Pfizer
  • PharmaJet
  • Pharmstandard
  • Polfa Tarchomin
  • Regeneron
  • Rhone Poulenc-Rorer
  • Roehr Products
  • Roselabs Bioscience
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Schott
  • Schott Kaisha
  • Schott Xinkang Pharmaceutical Packaging
  • SciGen
  • Shanghai Celgen Bio-Pharmaceutical
  • Shanghai CP Guojin
  • SHL Group
  • Square Pharmaceuticals
  • Stevanato Group (Ompi)
  • Takeda Pharmaceutical
  • Terumo
  • Teva Pharmaceutical
  • Tonghua Dongbao
  • UCB
  • Unlife
  • Vetter
  • Vetter Pharma
  • Weigao
  • West Pharmaceuticals
  • Wockhardt
  • Ypsomed
  • Zeon

Organisations Mentioned in the Report

  • Battele Memorial Institute
  • Carl Zeiss Foundation
  • Centers for Disease Control (US)
  • European Society of Cardiology
  • National Health Service (UK)
  • Parenteral Drug Association
  • PATH
  • UNICEF
  • US Agency for International Development
  • US Federal Drug Administration
  • World Health Organization
Back to Top